Core Viewpoint - The resignation of Jiang Yi and Jiang Qian from their positions at Kang En Bei is attributed to "work adjustments," raising concerns about the company's leadership stability and governance structure [2][3][7]. Group 1: Resignation Details - Jiang Yi, the chairman and legal representative, and Jiang Qian, a board member, submitted their resignation reports, effective immediately, and will no longer hold any positions within the company [2][3]. - The board has approved the nomination of Xu Jie and Jin Junli as candidates for non-independent directors, to be voted on at the upcoming shareholder meeting on December 22 [2][4]. Group 2: Company Performance - Kang En Bei reported a revenue of 4.976 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 1.27%, while net profit attributable to shareholders reached 584 million yuan, up 12.65% [3]. - The increase in net profit outpaced revenue growth due to improved performance in core business operations and an increase in the market value of shares held in Jiahe Biological [3]. Group 3: Leadership Changes - The company has experienced frequent changes in its leadership over the past two years, with Jiang Yi's tenure as chairman lasting just over a year [5][6]. - Jiang Yi succeeded Hu Jiqiang, who had been a pivotal figure in the company for nearly 40 years, guiding its strategic direction and growth [6][7]. Group 4: Governance Structure - The governance structure of Kang En Bei has undergone significant changes since the Zhejiang Provincial Foreign Trade Group took control in 2020, leading to a transition of management from Hu Jiqiang to Jiang Yi [7].

Core Viewpoint - The report from Zheshang Securities indicates that Kang En Bei's revenue growth rates for Q1-Q3 2025 are projected to be -7.64%, +3.04%, and +10.42% year-on-year, showing continuous improvement quarter-on-quarter [1] Group 1: Revenue Performance - The significant drag on the company's performance in the first half of 2025 is primarily due to the high base effect from the flu season in the first half of 2024, particularly affecting the "Jin Di" brand of compound Houttuynia cordata syrup and other respiratory medications [1] - In contrast, digestive and metabolic medications such as Chang Yan Ning achieved a year-on-year growth of 16.51% in the first half of 2025 [1] Group 2: Future Outlook - Looking ahead to Q4 2025 and 2026, it is expected that with the normalization of flu data and the ongoing deepening of the mixed reform process, along with the steady advancement of the brand focus strategy, brand products are likely to see stable growth [1] - National sentinel hospital data indicates an increase in flu-like cases in both northern and southern provinces since late October 2025, surpassing the levels of the same period in 2024, which is expected to benefit the company's core business [1] Group 3: Product Impact and Strategy - The company's core products, including the "Kang En Bei" Chang Yan Ning series and "Jin Di" compound Houttuynia cordata series, are OTC products that are less affected by centralized procurement price reductions [1] - As the proportion of specialty health consumer products continues to rise, the impact of centralized procurement is expected to diminish [1] - The company maintains an "Overweight" rating [1]